ArticleCurrent research in toxicology2020
Luminespib counteracts the Kifunensine-induced lung endothelial barrier dysfunction.
Article in Current research in toxicology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 23 citations in OpenAlex.
- Growth hormone - releasing hormone in the immune system.Reviews in endocrine & metabolic disorders · 2025Review
- Endothelial Unfolded Protein Response-Mediated Cytoskeletal Effects.Cell biochemistry and function · 2024Review
- Unfolded protein response suppression potentiates LPS-induced barrier dysfunction and inflammation in bovine pulmonary artery endothelial cells.Tissue barriers · 2024Article
- Growth hormone - releasing hormone in the context of inflammation and redox biology.Frontiers in immunology · 2024Article
- Ceapin-A7 potentiates lipopolysaccharide-induced endothelial injury.Journal of biochemical and molecular toxicology · 2023Article
- The vascular perspective on acute and chronic lung disease.The Journal of clinical investigation · 2023Review
- Heat shock protein 90 inhibition in the endothelium.Frontiers in medicine · 2023Article
- P53 in endothelial function and unfolded protein response regulation.Cell biology international · 2022Article
- Activating transcription factor 6 protects against endothelial barrier dysfunction.Cellular signalling · 2022Article
- Unfolded protein response in endothelial injury.Cell cycle (Georgetown, Tex.) · 2022Article
- Hsp90 inhibition protects brain endothelial cells against LPS-induced injury.BioFactors (Oxford, England) · 2022Article
- Tunicamycin Protects against LPS-Induced Lung Injury.Pharmaceuticals (Basel, Switzerland) · 2022Article
- P53 mediates the protective effects of metformin in inflamed lung endothelial cells.International immunopharmacology · 2021Article
- Suppression of reactive oxygen species in endothelial cells by an antagonist of growth hormone-releasing hormone.Journal of biochemical and molecular toxicology · 2021Article
- Brefeldin A and kifunensine modulate LPS-induced lung endothelial hyperpermeability in human and bovine cells.American journal of physiology. Cell physiology · 2021Article
- Unfolded Protein Response: A Regulator of the Endothelial Barrier.Endocrine and metabolic science · 2021Article
- Restoring the endothelial barrier function in the elderly.Mechanisms of ageing and development · 2021Review
- Growth Hormone Releasing Hormone in Endothelial Barrier Function.Trends in endocrinology and metabolism: TEM · 2021Article
- Unfolded protein response in the COVID-19 context.Aging and health research · 2021Article
- Hsp90 inhibition protects the brain microvascular endothelium against oxidative stress.Brain disorders (Amsterdam, Netherlands) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Unfolded protein response (UPR) suppression by Kifunensine has been associated with lung hyperpermeability, the hallmark of Acute Respiratory Distress Syndrome. The present study investigates the effects of the heat shock protein 90 inhibitor Luminespib (AUY-922) towards the Kifunensine-triggered lung endothelial dysfunction. Our results indicate that the UPR inducer Luminespib counteracts the effects of Kifunensine in both human and bovine lung endothelial cells. Hence, we suggest that UPR manipulation may serve as a promising therapeutic strategy against potentially lethal respiratory disorders, including the ARDS related to COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.